Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Accept all cookies Reject all non-essential cookies

Publications

Nivolumab for Relapsed or Refractory Classical Hodgkin Lymphoma (cHL) after Autologous Hematopoietic Cell Transplantation (auto-HCT): Extended Follow-up of the Phase 2 Single-Arm CheckMate 205 Study

Armand P. et al, (2018), BLOOD, 132

Nivolumab Treatment Beyond Investigator-Assessed Progression: Extended Follow-up in Patients with Relapsed/Refractory Classical Hodgkin Lymphoma from the Phase 2 CheckMate 205 Study

Cohen JB. et al, (2018), BLOOD, 132

Phase 1 Study of Adct-301 (Camidanlumab Tesirine), a Novel Pyrrolobenzodiazepine-Based Antibody Drug Conjugate, in Relapsed/Refractory Classical Hodgkin Lymphoma

Hamadani M. et al, (2018), BLOOD, 132

Spliceosome Mutations Are Common in MPN-Associated Myelofibrosis with RBC-Transfusion-Dependence and Correlate with Response to Pomalidomide

Chowdhury O. et al, (2018), BLOOD, 132

A guideline for the diagnosis and management of polycythaemia vera

MEAD AJ. et al, (2018), British Journal of Haematology

Unraveling intratumoral heterogeneity through high-sensitivity single-cell mutational analysis and parallel RNA-sequencing

Rodriguez-Meira A. et al, (2018), Molecular Cell

Challenges in assessing response of oesophageal cancer to neoadjuvant therapy, and the potential of composite PET-CT and multimodal metrics

(2018), Journal of Thoracic Disease

Interim pharmacokinetic (PK) and pharmacodynamic (PD) data from the first-in-human study of NUC-3373, a pyrimidine nucleotide analogue, in patients with advanced solid tumors

(2018), Annals of Oncology

MErCuRIC1: A phase 1a study of MEK1/2 inhibitor PD-0325901 with cMET inhibitor crizotinib in patients with advanced solid tumours

(2018), Annals of Oncology

Paclitaxel with or without trametinib or pazopanib in advanced wild-type BRAF Melanoma (PACMEL): a multicentre, open-label, randomised, controlled phase II trial.

Urbonas V. et al, (2018), Annals of oncology : official journal of the European Society for Medical Oncology

Phase II trial Paclitaxel with or without trametinib or pazopanib in advanced wild-type BRAF Melanoma (PACMEL): a multicentre, open-label, randomised, controlled phase II trial

MIDDLETON MR. et al, (2018), Annals of Oncology

A guideline for the management of specific situations in polycythaemia vera and secondary erythrocytosis

MEAD AJ. et al, (2018), British Journal of Haematology

RIVA - a phase IIa study of rituximab and varlilumab in relapsed or refractory B-cell malignancies: study protocol for a randomized controlled trial.

Lim SH. et al, (2018), Trials, 19

Adjuvant therapy with nivolumab versus ipilimumab after complete resection of stage III/IV melanoma: Updated results from a phase 3 trial (CheckMate 238)

Weber JS. et al, (2018), BRITISH JOURNAL OF CANCER, 119, 41 - 42

A Phase I dose-finding and safety study of AZD8931 with Oxaliplatin and Capecitabine chemotherapy in patients with Oesophago-gastric adenocarcinoma: the randomised expansion phase of the DEBIOC trial

Thomas A. et al, (2018)

VCAM-1 targeted magnetic resonance imaging enables detection of brain micrometastases from different primary tumours

CHENG VWT. et al, (2018), Clinical Cancer Research

A phase I dose escalation multi-centre study of crizotinib (MET inhibitor) combined with binimetinib (MEK inhibitor) in patients with advanced solid tumours

Wilson R. et al, (2018), EUROPEAN JOURNAL OF CANCER, 103, E140 - E141

A study of the focal adhesion kinase inhibitor GSK2256098 in patients with recurrent glioblastoma with evaluation of tumor penetration of [11C]GSK2256098.

Brown NF. et al, (2018), Neuro-oncology, 20, 1634 - 1642

CD47 Blockade by Hu5F9-G4 and Rituximab in Non-Hodgkin's Lymphoma.

Advani R. et al, (2018), N Engl J Med, 379, 1711 - 1721

Long-term survival with anti-PD-1-based immunotherapy, but what is the best approach?

Middleton MR., (2018), Lancet Oncol, 19, 1424 - 1426